Inotuzumab ozogamicin population PK
A two-compartment population PK model for inotuzumab ozogamicin with linear and time-dependent clearance and clinically relevant body-size and disease covariates.
- Therapeutic
- Inotuzumab ozogamicin
- Target
- SIGLEC2, CD22, B-cell receptor CD22
- Disease
- B-cell acute lymphoblastic leukemia and B-cell lymphoma
Biological model
A two-compartment population PK model for inotuzumab ozogamicin with linear and time-dependent clearance and clinically relevant body-size and disease covariates.
Intervention
Inotuzumab ozogamicin
Biological focus
SIGLEC2, CD22, B-cell receptor CD22
Context
B-cell acute lymphoblastic leukemia and B-cell lymphoma
Model details
A two-compartment population PK model for inotuzumab ozogamicin with linear and time-dependent clearance and clinically relevant body-size and disease covariates.
Modeled states
- AUC ng h mLng*h/mL
Modeled dynamic state for auc ng h ml.
- A central mgmg
Modeled dynamic state for a central mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
- elapsed time hh
Modeled dynamic state for elapsed time h.
Key readouts
- Central inotuzumab ozogamicinunknown
Model-derived readout for central inotuzumab ozogamicin.
- Cumulative ADC exposureng*h/mL
Model-derived readout for cumulative adc exposure.
- Total clearanceunknown
Model-derived readout for total clearance.
- Clearance-desensitization rateunknown
Model-derived readout for clearance-desensitization rate.
- A central mgmg
Model-derived readout for a central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
ALL 1.8 mg/m2/cycle fractionated regimen dynamic
How do regimen and time-dependent clearance shape inotuzumab ozogamicin concentration and exposure? Explore this intervention regimen through Central inotuzumab ozogamicin, Cumulative ADC exposure, Total clearance, Clearance-desensitization rate. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do regimen and time-dependent clearance shape inotuzumab ozogamicin concentration and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do regimen and time-dependent clearance shape inotuzumab ozogamicin concentration and exposure?
CL1 base L h
Model parameter controlling cl1 base l h.
Exploratory range around the default value.
5 evenly spaced values in L/h. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphomaJournal of Pharmacokinetics and Pharmacodynamics
